Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 10
Submit an article Journal homepage
91
Views
29
CrossRef citations to date
0
Altmetric
Research Article

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with Poor-prognosis Acute Myeloid Leukemia

G.J. Roboz Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY, USA
,
M.A. Knovich Wake Forest University School of Medicine, Winston-Salem, NC, USA
,
R.L. Bayer Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY, USA
,
M.W. Schuster Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY, USA
,
K. Seiter New York Medical College, Valhalla, NY, USA
,
B.L. Powell Wake Forest University School of Medicine, Winston-Salem, NC, USA
,
R.D. Woodruff Wake Forest University School of Medicine, Winston-Salem, NC, USA
,
R.T. Silver Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY, USA
,
A.E. Frankel Wake Forest University School of Medicine, Winston-Salem, NC, USA
&
E.J. Feldman Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY, USA
 show all
Pages 1951-1955 | Published online: 03 Aug 2009

  • [Line 8536]Estey, E.H. (2000) "Treatment of relapsed and refractory acute myelogenous leukemia". Leukemia 14, 476-479.
  • [Line 8564]Vey, N., Keating, M., Giles, F., et al. (1999) "Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy". Blood 39, 3149-3150.
  • [Line 8594]Schiffer, CA., Lee, E.J., Tomiyasu, T., et al. (1989) "Prognostic impact of cytogcnetic abnormalities in patients with de novo acute nonlymphocytic leukemia". Blood 73, 263-270.
  • [Line 8624]Dastugue, N., Payen, C., Lafage-Pochitaloff, M., et al. (1995) "Prognostic significance of karyotype in de novo adult acute mycloid leukemia". Leukemia 9, 1491-1498.
  • [Line 8654]Fenaux, P., Preudhomme, C., Lai, J.L., et al. (1989) "Cytogenetics and their prognostic value in de novo acute myeloid leukemia: a report on 283 cases", Br. J. Haemaol. 73, 61-67.
  • [Line 8684]Hiddemann, W., Kern, W., Schoch, C., et al (1999) "Management of acute myeloid leukemia in elderly patients", J. Clin. Oncol. 17, 3569-3576.
  • [Line 8714]Baudard, M., Marie, J.P., Cadiou, M., et al. (1994) "Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients". Br. J. Haematol. 86, 82-91.
  • [Line 8744]Hoyle, C.F., de Bastos, M., Wheatley, K., et al. (1989) "AML associated with previous cytotoxic therapy. MDS or myeloproliferative disorders: results from the MRC's 9th AML trial". Br. J. Haematol. 72, 45-53.
  • [Line 8774]Hamblin, T.J. (1992) "The treatment of acute myeloid leukemia preceded by the myelodysplastic syndrome". Leuk. Res. 16, 4101-4108.
  • [Line 8802]Leith, C.P. Kopecky, K.J., Godwin, J., et al. (1997) "Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MRDI) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy, a Southwest Oncology Group study". Blood 89, 3323-3329.
  • [Line 8832]DeLima, M., Ghaddar, H., Pierce, S., et al. (1996) "Treatment of newly diagnosed acute myelogenous leukemia in patients aged 80 years and above". Br J Haematol. 93, 89-95.
  • [Line 8862]Sievers, E.L., Appelbaum, F.R., Spielberger, R.T., et al. (1999) "Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate". Blood 93, 3678-3684.
  • [Line 8892]Andrews, R.G., Singer, J.W. and Bernstein, J.D. (1989) "Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties". J. Exp. Med. 169, 1721-1731.
  • [Line 8922]Dinndorf, P.A., Andrews, R.G., Benjamin, D., et al. (1986) "Expression of normal myeloid-associated antigens by acute leukemia cells". Blood 67, 1048-1053.
  • [Line 8952]Dedon, P. (2000) "Mechanism of calicheamicin-induced cytotoxicity". Biol. Ther. Leuk. 1, 1-8.
  • [Line 8980]Sievers, E.I., Larson, R.A., Estey, E., et al. (1999) "Efficacy and safety of CMA-676 in patients with AML in first relapse". Blood 94 (Suppl. 1). 696a. (abstr).
  • Physicians' Desk Reference Edition 55. (2001) (Medical Economics Company, New Jersey), pp 3404-3407.
  • [Line 9032]Estey, E.H. (2000) "How I treat elderly patients with AML". Blood 96, 1670-1673.
  • [Line 9060]Lowenberg, B., Zittoun, R., Kerkhofs, H., et al. (1989) "On the value of intensive remission induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group". J. Clin. Oncol. 9, 1268-1274.
  • [Line 9090]Spataro, V., Kovacsovics, T., Bach, S., et al. (2000) "Acute mycloid leukemia in the elderly: results of an individualized approach in two centers", Leukemia 39, 521-530.
  • [Line 9120]Cohen, A.D., Luger, S.M. and Mangan, P.A. (2000) "CMA-676 as monotherapy fur patients with poor prognosis AML (abstract)". Blood 96, 1400a.
  • [Line 9148]Paciucci, P.A., Cuttner, J. and Holland, J.F. (1984) "Mitoxantrone as a single agent and in combination chemotherapy of patients with refractory acute leukemia". Semin, Oncol. 11, 36-40.
  • [Line 9178]Arlin, Z.A., Silver, R.T. and Cassileth, P. (1985) "Phase I-II trial of mitoxantrone in acute leukemia". Cancer Treat. Rep. 69, 61-64.
  • [Line 9208]Carella, A.M., Bernum, E., Maraone, M.P., et al. (1990) "ldarubicin in the treatment of acute leukemias: An overview of preclinical and clinical studies". Haematologica 75, 159-169.
  • [Line 9238]Karanes, C., Kopecky, K.J., Head, D.R., et al. (1999) "A phase III comparison of high dose ARA-C (HIDAC) versus, HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group study". Leuk. Res. 23, 787-794.
  • [Line 9268]Estey, E.H., Komblau, S., Pierce, S., et al. (1996) "A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia". Blood 88, 756.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.